Poly Medicure Ltd.
NSE: POLYMEDPoly Medicure Ltd.: A 30-second snapshot
Poly Medicure trades at ₹1,667.20, up 4.41% over the trailing 3 months and above both its 50-DMA (₹1,577.13) and 200-DMA (₹1,608.98), but remains 22.13% below its 52-week high and down 15.19% over the past 12 months. Trailing PE of 53.72x sits mid-to-upper range against listed Pharma/medtech peers (28.9x-74.6x), while the company shows zero years of positive free cash flow and a 5-year earnings CAGR of -26.8% despite 21.3% revenue growth over the same period. No news headlines were logged for this stock in the current analysis cycle.
P/E
53.7
Forward P/E
36.2
ROE
+10.8%
Debt / Equity
11.23
Profit Margin
+17.2%
Div. Yield
+0.2%
5Y ROE > 15%
1/5
5Y FCF > 0
0/5
Quality
45/100
Recent context
- ·No news headlines were captured for Poly Medicure in this analysis cycle (0 total, positive/neutral/negative all 0).
- ·Analyst consensus rating field is null this cycle despite a tracked coverage count of 6 analysts.
- ·Price has recovered 4.41% over the trailing 3 months after a 22.13% drawdown from its 52-week high, moving back above both the 50- and 200-day moving averages.
Strengths
- +Revenue has grown at a 21.3% 5-year CAGR.
- +Price trades above both the 50-DMA (₹1,577.13) and 200-DMA (₹1,608.98), with a 4.41% gain over the trailing 3 months.
- +Profit margin of 17.18%, and a forward PE of 36.19x below the 53.72x trailing multiple, implying analysts model earnings expansion ahead.
- +Debt-to-equity of 0.11x is low in absolute terms even though the multi-year trend is classified as rising.
Weaknesses
- −Zero years of positive free cash flow across the tracked history, alongside a debt trend classified as rising.
- −5-year earnings CAGR of -26.8% despite 5-year revenue growth of +21.3% over the same period — revenue growth has not converted into earnings.
- −ROE of 10.85%, with only 1 of the tracked years above the 15% threshold and a consistency score of 42; quality score of 31 ranks 4th of 6 listed Pharma/medtech peers.
- −Trailing PE of 53.72x sits above Dr. Reddy's (28.9x), Cipla (35.4x) and Sun Pharma (41.6x), even as trailing earnings have contracted over 5 years.
Open questions
- ?What is driving the divergence between 21.3% revenue growth and -26.8% earnings growth over the same 5-year window — margin compression, one-off charges, or something structural?
- ?Why has the company recorded zero years of positive free cash flow despite a reported profit margin of 17.18%, and how is the rising debt trend being funded?
- ?Does the 53.72x trailing PE, priced above most listed Pharma/medtech peers, reflect the 36.19x forward multiple's implied earnings recovery, or a re-rating that has run ahead of fundamentals?
- ?With no fresh news flow and an unavailable analyst consensus this cycle, what upcoming catalysts (quarterly results, sector policy, regulatory filings) could next move the stock materially?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| POLYMED | Poly Medicure Ltd.You're viewing | 53.7 | +10.8% | 31 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹1,667.20
SMA 50
₹1,577.13
SMA 200
₹1,608.98
RSI (14)
52.3 (neutral)
From 52w high
-22.1%
1Y return
-15.2%
3M return
+4.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highZero years of positive free cash flow across the tracked history (fcfPositiveYears = 0), combined with a debt trend classified as rising and a 5-year earnings CAGR of -26.8% against 5-year revenue growth of +21.3% over the same period — revenue expansion has not converted into cash generation or earnings growth.
- mediumROE of 10.85%, with only 1 of the tracked years showing ROE above 15% and a consistency score of 42; quality score of 31 ranks 4th of 6 Pharma/medtech peers listed (Apollo Hospitals, Cipla, Dr. Reddy's, Max Healthcare, Sun Pharma).
- mediumTrailing PE of 53.72x sits above most listed Pharma/medtech peers (Dr. Reddy's 28.9x, Cipla 35.4x, Sun Pharma 41.6x; Apollo Hospitals 66.4x and Max Healthcare 74.6x are higher) while trailing 5-year earnings have contracted -26.8%; forward PE of 36.19x implies a lower multiple is expected if earnings recover.
- lowNews section returned zero headlines this cycle (total = 0, positive/neutral/negative all 0), and the analyst consensus rating field is null despite a tracked coverage count of 6 — narrative below relies on fundamentals, technicals and sector data only.
Cross-section contradictions
- 5-year revenue growth of +21.3% and 5-year earnings growth of -26.8% move in opposite directions over the same window, indicating that top-line expansion has not translated into earnings growth — a structural divergence rather than a single-period anomaly.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days